Risk factors for the development of glucocorticoid-induced diabetes mellitus
- PMID: 25765669
- DOI: 10.1016/j.diabres.2015.02.010
Risk factors for the development of glucocorticoid-induced diabetes mellitus
Abstract
Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM.
Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors.
Results: During a four-week period, 84 of the 128 patients (65.6%) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p<0.0001), higher levels of fasting plasma glucose (93.3 vs. 89.0mg/dl, p=0.027) and HbA1c (5.78 vs. 5.50%, 39.7 vs. 36.6 mmol/mol, p=0.001) and lower eGFR values (54.0 vs. 77.1 ml/min/1.73 m(2), p=0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0%) and lower eGFR (<40 ml/min/1.73m(2)) were identified as independent risk factors for GC-DM (OR 2.95, 95% CI 1.15-7.92, OR: 3.05, 95% CI 1.11-9.21, OR: 3.42, 95% CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM.
Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered.
Keywords: Glucocorticoid-induced diabetes mellitus; Renal disease; Rheumatic disease; Risk factor.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases.Nephron Clin Pract. 2007;105(2):c54-7. doi: 10.1159/000097598. Epub 2006 Nov 29. Nephron Clin Pract. 2007. PMID: 17135768
-
Current smoking is an independent risk factor for new-onset diabetes mellitus during highdose glucocorticoid treatment.Int J Clin Pharmacol Ther. 2015 Aug;53(8):616-20. doi: 10.5414/CP202136. Int J Clin Pharmacol Ther. 2015. PMID: 25997545
-
A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy.PLoS One. 2017 May 31;12(5):e0178018. doi: 10.1371/journal.pone.0178018. eCollection 2017. PLoS One. 2017. PMID: 28562629 Free PMC article.
-
[Glucocorticoid-induced diabetes and risk factors during high-dose therapy].Ugeskr Laeger. 2018 Apr 30;180(18):V06170454. Ugeskr Laeger. 2018. PMID: 29720341 Review. Danish.
-
Glucocorticoid-induced hyperglycemia.Am J Med Sci. 2013 Apr;345(4):274-277. doi: 10.1097/MAJ.0b013e31828a6a01. Am J Med Sci. 2013. PMID: 23531958 Review.
Cited by
-
Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.Rheumatol Int. 2018 Apr;38(4):569-577. doi: 10.1007/s00296-017-3874-3. Epub 2017 Nov 9. Rheumatol Int. 2018. PMID: 29124397
-
Glycated haemoglobin and serum fructosamine concentrations in sick, non-diabetic dogs receiving oral prednisolone.Vet Rec. 2025 Jan 18;196(2):e4843. doi: 10.1002/vetr.4843. Epub 2024 Dec 2. Vet Rec. 2025. PMID: 39618192 Free PMC article.
-
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions.Nat Rev Endocrinol. 2022 Sep;18(9):540-557. doi: 10.1038/s41574-022-00683-6. Epub 2022 May 18. Nat Rev Endocrinol. 2022. PMID: 35585199 Free PMC article. Review.
-
[Other specific types of diabetes and exocrine pancreatic insufficiency (Update 2019)].Wien Klin Wochenschr. 2019 May;131(Suppl 1):16-26. doi: 10.1007/s00508-019-1454-0. Wien Klin Wochenschr. 2019. PMID: 30980164 Review. German.
-
Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?Front Endocrinol (Lausanne). 2021 Jun 18;12:649405. doi: 10.3389/fendo.2021.649405. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220705 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous